Cochrane · systematic review · CD012116
Acetylsalicylic acid (aspirin) for schizophrenia
Schmidt, L, Phelps, E, Friedel, J, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
5
No studies
2
Included studies
NR
No studies 2 · 28.6%Ungraded 0 · 0%Very low 5 · 71.4%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Aspirin plus antipsychotics compared to placebo plus antipsychotics for people with schizophrenia
Population: people with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: any change in global state – unspecified problem necessitating change in dose or type of antipsychotics – medium term Aspirin plus antipsychotics vs placebo plus antipsychotics | RR 0.75 [0.3, 1.88] | 1 study · 70 participants | Very low Downgraded: imprecision, indirectness, publication bias |
Mental state: general – mean endpoint score (PANSS total, high = poor) – medium term Aspirin plus antipsychotics vs placebo plus antipsychotics | no estimate extracted | 2 studies · 130 participants | Very low Downgraded: imprecision, indirectness, publication bias |
Cognitive functioning: clinically important change in cognitive functioning Aspirin plus antipsychotics vs placebo plus antipsychotics | no estimate extracted | NR | No studies |
Leaving the study early: short‐term – for any reason Aspirin plus antipsychotics vs placebo plus antipsychotics | RR 1.12 [0.4, 3.14] | 2 studies · 130 participants | Very low Downgraded: imprecision, publication bias |
Adverse events: gastrointestinal – dyspeptic symptoms – self‐assessed as at least 'moderate' Aspirin plus antipsychotics vs placebo plus antipsychotics | RR 1.03 [0.55, 1.94] | 1 study · 70 participants | Very low Downgraded: imprecision, publication bias |
Quality of life: clinically important change Aspirin plus antipsychotics vs placebo plus antipsychotics | no estimate extracted | NR | No studies |
Service use: change in hospital status – any change Aspirin plus antipsychotics vs placebo plus antipsychotics | RR 0.56 [0.05, 5.9] | 1 study · 70 participants | Very low Downgraded: imprecision, indirectness, publication bias |